Organic Active Ingredients TRIZ Cases

Synergistic dissolution in mixed solvents increases API concentration while maintaining stability during spray drying.

A parenteral lipid emulsion uses omega-3 ethyl esters with anionic and amphoteric surfactants to form a stable oil-in-water dispersion.

Oral halofuginone replaces intravenous Remdesivir to prevent severe respiratory disease by blocking heparan sulfate biosynthesis.

Formula I compounds inhibit protein kinase activity to reduce cancer cell proliferation while sparing normal cells from damage.

Short peptides with histidine residues form nanoparticles that dissolve at tumor pH, protecting cargo from enzymatic degradation and avoiding immune clearance.

Heterocyclic substitution at the 3-position of nicotinic acid reduces flushing and diarrhea while maintaining therapeutic efficacy.

Thymidine phosphorylase inhibitors prevent rapid FTD breakdown, resolving the contradiction between short half-life and therapeutic reliability.

Topical formulation utilizes diffusing agents to transport active ingredients across the intact tympanic membrane, eliminating invasive injection risks.

Small molecule inhibitors reduce PD-L1 levels to overcome tumor burden limitations and improve therapeutic responses in advanced malignant tumors.

Dabigatran mitigates cognitive decline by blocking vascular activation and reducing inflammatory protein production.

Pharmaceutical composition stabilizes excitable cell membrane potential via repolarization to treat specific autism subtypes.

Merges antifungal drugs with adhesion inhibitors to block Candida attachment, reducing recurrence and pain.

Combining KRAS G12C modulators with EGFR or PI3K inhibitors overcomes the limitation of monotherapy by inducing robust apoptosis in resistant tumors.

Bifidobacterium longum ATCC BAA-999 modulates gut microbiota to treat functional gastrointestinal disorders.

A monoclonal antibody against PD-1 with specific Fc fragment mutations enhances binding affinity to the neonatal Fc Receptor.

Substituted oxazole derivatives resolve solubility and stability trade-offs while maintaining potent spleen tyrosine kinase inhibition.

Specific substituted beta-hydroxy amides inhibit PRMT5 activity to treat cancers and hemoglobinopathies by regulating arginine methylation.

Porous polymer beads capture endotoxins through tortuous paths, preventing harmful substance leaching while simultaneously removing cytokines.

A modified alginate hydrogel encapsulates bioactive substances for targeted intestinal release.

Assays detect Mena protein isoforms in biological samples to identify metastatic tumors.

A biodissolvable mucoadhesive film adheres to the vulvar vestibule to sustain lidocaine release.

Affinity protein complexes regulate drug release from red blood cells, reducing premature hepatic metabolism and side effects.

Resorcinol derivatives achieve effective skin lightening at low concentrations by inhibiting tyrosinase activity without cytotoxicity.

Aptamers block PD-1:PDL1 interaction to suppress tumor growth, resolving the trade-off between molecular weight and tissue penetration.

Ipidacrine formulations inhibit cholinesterase to increase acetylcholine, addressing stress-induced sexual dysfunction.

Activated charcoal adsorbs fishy odors from polyunsaturated fatty acids, eliminating the need for complex taste masking technologies.

Aqueous hydrocortisone sodium phosphate solution with propylene glycol and sorbitol prevents microbial growth.

A therapeutic composition merges dexamethasone with RK-20449 to enhance leukemia cell killing rates.

Upregulating caveolin-1 expression increases glioblastoma cell sensitivity to temozolomide chemotherapy.

Alkylated tetrahydropyrans provide intense freshening while neutralizing bitter medicinal tastes.

Novel oxalyl piperazine compounds inhibit hepatitis B virus replication by targeting the capsid protein, avoiding drug resistance and improving safety.

Selective oxidation of protected morphine derivatives yields high-purity noroxymorphone, reducing side-products from inefficient multi-step methods.

Fluorescent in situ hybridization identifies the SLC34A2-ROS fusion kinase to enable targeted therapy selection for non-small cell lung carcinoma patients.

Esters of 7-carboxy cannabidiol act as GPR3 antagonists to reduce neurotoxic protein production.

GPR40 agonist phenyl propionic acid derivatives modulate blood glucose levels by inducing dynamic insulin secretion, avoiding hypoglycemia risks.

New polymorphic structures resolve hygroscopicity issues in Rho kinase inhibitors, ensuring reliable manufacturing.

Crystallization from formic acid and water purifies bromodomain inhibitors, eliminating column chromatography to boost yield.

Methyl cyclodextrin compositions elevate HDL cholesterol to reduce atheromatous plaques without phospholipid vesicles.

Citrate acts as an external electron acceptor to accelerate reconstitution of freeze-dried lactic acid bacteria.

AP1189 targets melanocortin receptors MC1R and MC3R on podocytes to reduce proteinuria without steroidogenic side effects.

Extracellular vesicles from Lactobacillus paracasei GM-080 suppress allergic reactions by resolving inconsistent probiotic efficacy.

Segmenting placental vasculature into decellularized scaffolds preserves structural integrity while enabling stable protein production for tissue replacement.

Splice modulating oligonucleotides reduce SCN8A function to rebalance excitatory and inhibitory neuronal imbalances in Dravet Spectrum disorders.

D-gluconic acid inhibits hydrolytic degradation of rocuronium, enabling thermal sterilization and room temperature storage without cool chain logistics.